Jeffrey Schriber
Impact in
- Hematology top 1%
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Transplantation top 5%
Papers in
- Hematology 15
- Hematopoietic Stem Cell Transplantation 10
- Chronic Myeloid Leukemia Treatments 5
- Acute Myeloid Leukemia Research 3
- Multiple Myeloma Research and Treatments 3
-
- Renal Transplantation Outcomes and Treatments 3
- Co-authors
- Paul ShaughnessyMark R. LitzowBipin N. SavaniJ. Douglas RizzoPaul A. CarpenterKaren K. BallenYago NietoPaul J. Martin
- Journals
- Biology of Blood and Marrow Transplantation (11 papers)Blood (4 papers)Cancer (3 papers)Journal of Clinical Oncology (1 paper)Drug Safety (1 paper)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Jeffrey Schriber
22 papers receiving 1.1k citations
Hit Papers
Peers
Comparison fields: 5 of 85
- Hematology 744
- Transplantation 69
- Genetics 218
- Immunology 324
- Oncology 333
Countries citing papers authored by Jeffrey Schriber
This map shows the geographic impact of Jeffrey Schriber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Schriber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Schriber more than expected).
Fields of papers citing papers by Jeffrey Schriber
This network shows the impact of papers produced by Jeffrey Schriber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Schriber. The network helps show where Jeffrey Schriber may publish in the future.
Co-authors
The 25 scholars most cited alongside Jeffrey Schriber, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 1 | |
| 2 | 2018 | 7 | |
| 3 | 2017 | 1 | |
| 4 | 2015 | 56 | |
| 5 | 2013 | 252 | |
| 6 | First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation Hit paper breakdown → | 2012 | 423 |
| 7 | 2010 | 15 | |
| 8 | 2010 | 62 | |
| 9 | 2008 | 52 | |
| 10 | 2008 | 1 | |
| 11 | 2006 | 8 | |
| 12 | 2005 | 17 | |
| 13 | 2004 | 41 | |
| 14 | 1998 | 1 | |
| 15 | 1998 | 32 | |
| 16 | Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy. | 1998 | 30 |
| 17 | 1997 | 67 | |
| 18 | 1995 | 12 | |
| 19 | 1993 | 15 | |
| 20 | 1992 | 2 |
About Jeffrey Schriber
Jeffrey Schriber is a scholar working on Hematology, Transplantation, Genetics, Pathology and Forensic Medicine and Oncology, having authored 22 papers that have together received 1.1k indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (10 papers), Chronic Myeloid Leukemia Treatments (5 papers), Lymphoma Diagnosis and Treatment (4 papers), Acute Myeloid Leukemia Research (3 papers), Renal Transplantation Outcomes and Treatments (3 papers), Multiple Myeloma Research and Treatments (3 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Immune Cell Function and Interaction (2 papers). The work is most often cited by research in Hematology (744 citations), Transplantation (69 citations), Genetics (218 citations), Immunology (324 citations) and Oncology (333 citations). Jeffrey Schriber has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Paul Shaughnessy, Mark R. Litzow, Bipin N. Savani, J. Douglas Rizzo, Paul A. Carpenter, Karen K. Ballen, Yago Nieto, Paul J. Martin, Donna A. Wall and John R. Wingard. Their work appears in journals such as Biology of Blood and Marrow Transplantation, Blood, Cancer, Journal of Clinical Oncology and Drug Safety.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.